Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Accounts Payables (2017 - 2025)

Bioceres Crop Solutions' Accounts Payables history spans 9 years, with the latest figure at $96.4 million for Q2 2025.

  • On a quarterly basis, Accounts Payables fell 42.85% to $96.4 million in Q2 2025 year-over-year; TTM through Jun 2025 was $96.4 million, a 42.85% decrease, with the full-year FY2025 number at $96.4 million, down 42.85% from a year prior.
  • Accounts Payables hit $96.4 million in Q2 2025 for Bioceres Crop Solutions, down from $168.7 million in the prior quarter.
  • Over the last five years, Accounts Payables for BIOX hit a ceiling of $168.7 million in Q2 2024 and a floor of $2.7 million in Q4 2021.
  • Historically, Accounts Payables has averaged $97.6 million across 5 years, with a median of $95.5 million in 2022.
  • Biggest five-year swings in Accounts Payables: surged 59.33% in 2023 and later crashed 42.85% in 2025.
  • Tracing BIOX's Accounts Payables over 5 years: stood at $2.7 million in 2021, then surged by 3422.63% to $94.7 million in 2022, then surged by 59.33% to $150.8 million in 2023, then increased by 11.89% to $168.7 million in 2024, then crashed by 42.85% to $96.4 million in 2025.
  • Business Quant data shows Accounts Payables for BIOX at $96.4 million in Q2 2025, $168.7 million in Q2 2024, and $150.8 million in Q2 2023.